Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Symmans

Showing results (41-50 of 96) with videos related to

Pageof 10
Sort By:
Cancer|July 25, 2007
Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D. Anderson experienceShaheenah Dawood, Ana M Gonzalez-Angulo, Florentia Peintinger, et al.
Breast Cancer Research and Treatment|July 16, 2009
Clinical evaluation of chemotherapy response predictors developed from breast cancer cell linesCornelia Liedtke, Jing Wang, Attila Tordai, et al.
Cancer|May 4, 2000
Invasive carcinoma in clinically suspicious breast masses diagnosed as adenocarcinoma by fine-needle aspirationD C Chhieng, G Fernandez, J F Cangiarella, et al.
Plos Medicine|December 14, 2016
Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic AnalysisTingting Jiang, Weiwei Shi, Vikram B Wali, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 23, 2013
Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus StatementH A Azim, S Michiels, F Zagouri, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 26, 2008
Modulation of ER phosphorylation on serine 118 by endocrine therapy: a new surrogate marker for efficacyM Zoubir, M C Mathieu, C Mazouni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 2, 2014
Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapyA Sheri, I E Smith, S R Johnston, et al.
Cancer Letters|May 8, 2025
ADAMs contribute to triple negative breast cancer via mTORC1 pathway: targeting ADAM-mTOR axis improves efficacyShuying Liu, Huiqin Chen, Mihai Gagea, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 9, 2008
Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable diseaseJulie R Gralow, Harold J Burstein, William Wood, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2001
Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine-needle aspiration: implications for early prediction of breast cancer response to neoadjuvant treatmentW F Symmans, M D Volm, R L Shapiro, et al.
Pageof 10

Showing results (41-50 of 96) with videos related to

Sort By:
Pageof 10
Cancer|July 25, 2007
Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D. Anderson experienceShaheenah Dawood, Ana M Gonzalez-Angulo, Florentia Peintinger, et al.
Breast Cancer Research and Treatment|July 16, 2009
Clinical evaluation of chemotherapy response predictors developed from breast cancer cell linesCornelia Liedtke, Jing Wang, Attila Tordai, et al.
Cancer|May 4, 2000
Invasive carcinoma in clinically suspicious breast masses diagnosed as adenocarcinoma by fine-needle aspirationD C Chhieng, G Fernandez, J F Cangiarella, et al.
Plos Medicine|December 14, 2016
Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic AnalysisTingting Jiang, Weiwei Shi, Vikram B Wali, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 23, 2013
Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus StatementH A Azim, S Michiels, F Zagouri, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 26, 2008
Modulation of ER phosphorylation on serine 118 by endocrine therapy: a new surrogate marker for efficacyM Zoubir, M C Mathieu, C Mazouni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 2, 2014
Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapyA Sheri, I E Smith, S R Johnston, et al.
Cancer Letters|May 8, 2025
ADAMs contribute to triple negative breast cancer via mTORC1 pathway: targeting ADAM-mTOR axis improves efficacyShuying Liu, Huiqin Chen, Mihai Gagea, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 9, 2008
Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable diseaseJulie R Gralow, Harold J Burstein, William Wood, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2001
Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine-needle aspiration: implications for early prediction of breast cancer response to neoadjuvant treatmentW F Symmans, M D Volm, R L Shapiro, et al.
Pageof 10